Related Experiment Videos
Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2
1Northwestern Medical School, Chicago, IL 60611.
Abstract:
Epstein-Barr Virus (EBV) causes infectious mononucleosis in normal adolescents and malignant B lymphocyte proliferation in immune compromised patients, in marmosets, or upon transfer of infected human B lymphocytes into SCID mice. EBV is also etiologically associated with African Burkitt's lymphoma, Hodgkin's Disease, and nasopharyngeal cancer. EBV transformed, latently infected B lymphocytes contain EBV episomes and eight virus encoded proteins. Six are nuclear proteins (EBNAs) and two are the integral membrane proteins, LMP1 and LMP2. These eight proteins are presumed to mediate latent virus infection or B lymphocyte proliferation and are thus under intense scrutiny. Besides EBNA1, which is required for episome maintenance, LMP1 and LMP2, are the two transformation associated proteins that are most consistently detected in EBV related malignancies, and the LMP2 message is the only message detected in PCR analysis of B lymphocytes from individuals harboring EBV latent infections. LMP2 associates with src family tyrosine kinases, a 70 kda cell phosphoprotein, LMP1 and several other unidentified cell proteins. LMP1 is a key mediator of EBV's effects on inducing B lymphocyte activation and adhesion molecules and is a transforming oncogene in rodent fibroblasts. The association of these two EBV encoded membrane proteins could create a macromolecular complex mediating constitutive B lymphocyte activation through normal cell signal transduction pathways. LMP2 might may control activation of lytic replication or down regulate the activation state of EBV infected cells allowing persistence in the human host.
Insights
Epstein-Barr Virus (EBV) proteins LMP1 and LMP2 are crucial for B cell proliferation and associated with cancers. Understanding their interactions may reveal new therapeutic targets for EBV-driven diseases.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Epstein-Barr Virus (EBV) causes infectious mononucleosis and is linked to various cancers, including Burkitt's lymphoma and nasopharyngeal carcinoma.
- Latently infected B lymphocytes harbor EBV episomes and express eight viral proteins, including nuclear proteins (EBNAs) and integral membrane proteins LMP1 and LMP2.
- LMP1 and LMP2 are consistently detected in EBV-related malignancies and are key to EBV's effects on B cells.
Purpose of the Study:
- To investigate the roles of EBV-encoded proteins, particularly LMP1 and LMP2, in B lymphocyte proliferation and malignant transformation.
- To understand the molecular interactions of LMP1 and LMP2 with cellular proteins and their potential involvement in signal transduction pathways.
- To explore the significance of LMP2 in maintaining latent EBV infections and its potential role in regulating viral replication or cell activation.
Main Methods:
- Analysis of EBV-encoded proteins, including EBNAs, LMP1, and LMP2, in infected B lymphocytes.
- Detection of LMP2 message using Polymerase Chain Reaction (PCR) in individuals with latent EBV infections.
- Investigating the association of LMP2 with src family tyrosine kinases and other cellular proteins.
- Assessing the transforming potential of LMP1 in rodent fibroblasts.
Main Results:
- LMP1 and LMP2 are the most consistently detected transformation-associated proteins in EBV-related malignancies.
- LMP2 message is the sole detectable EBV message in latent infections identified by PCR.
- LMP2 associates with src family tyrosine kinases, a 70 kDa phosphoprotein, LMP1, and other cellular proteins.
- LMP1 acts as a transforming oncogene and mediates B lymphocyte activation and adhesion.
Conclusions:
- The interaction between LMP1 and LMP2 may form a complex that drives constitutive B lymphocyte activation via cellular signal transduction pathways.
- LMP2 may play a role in controlling lytic replication or downregulating the activation state of EBV-infected cells, facilitating persistence.
- These EBV-encoded membrane proteins are critical mediators of EBV's oncogenic potential and B cell manipulation.